First synthesized in 2004 and patented by Pentapharm Ltd
Studies examining asthma, COPD and CF have focused on the role of the immune system [3,4,5,6,7] and epithelial ion channels in mucus secretion [8,9,10,11,12], but the involvement of the nervous system, and in particular neuropeptide signaling, remains a field of much unknowns [13]
Cyclin-dependent kinase inhibitor 2B mediates excitotoxicity-induced death of retinal ganglion cells
Optimized volume/price ratio, extended autonomy (several weeks at typical 250-500 mcg dose), final concentration adjustable to protocol (5 mg/ml with 2 ml bacteriostatic, or 2.5 mg/ml with 4 ml for finer dosing)
Heavy isotopes introduced in as L-arginine, L-ornithine, or other carbon/nitrogen donors to nitrergic metabolic pathways could in principle allow both on-target and off-target effects on nitrogen waste metabolism to be directly measured